Azithromycin

Drug Profile

Azithromycin

Alternative Names: Sumamed; Zithromax; Zithromax IV; Zytromax EV

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator PLIVA d.d.
  • Developer Cystic Fibrosis Foundation; Pfizer; St. Michaels Hospital; University of Wisconsin-Madison
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Pelvic inflammatory disorders; Sexually transmitted infections
  • No development reported Asthma; Cholera; Cystic fibrosis-associated respiratory tract infections; Gastroparesis; Pertussis; Typhoid
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastroparesis in Europe (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 06 Apr 2015 No recent reports on development identified - Phase-II for Cystic fibrosis-associated respiratory tract infections in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top